Testing effectiveness (Phase 2)Looking for participantsNCT06530550
What this trial is testing
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Who this might be right for
Lymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China 51